Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Corbus pharmaceuticals holdings, inc. crawled date : 2020 - 12 - 01 save search
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
Published: 2020-05-22 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 2.48%
H: 5.99%
C: 2.68%
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Published: 2020-05-27 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 1.25%
H: 0.99%
C: -5.18%
sclerosis phase 3 treatment
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
Published: 2020-06-01 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: -0.8%
H: 2.04%
C: -1.22%
disease phase 2b fibrosis cystic fibrosis
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
Published: 2020-06-22 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 1.43%
H: 2.25%
C: 0.64%
treatment phase 2b fibrosis cystic fibrosis
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
Published: 2020-06-29 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 0.64%
H: 5.22%
C: 0.76%
sclerosis
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
Published: 2020-07-08 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 0.0%
H: 0.37%
C: -1.12%
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
Published: 2020-07-29 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 1.02%
H: 0.72%
C: -7.2%
Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
Published: 2020-07-30 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 0.16%
H: 7.91%
C: 3.41%
results
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Published: 2020-08-03 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 2.39%
H: 8.1%
C: 5.76%
conference presentation
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Published: 2020-08-05 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 1.31%
H: 4.89%
C: 2.88%
phase 3 treatment enroll
Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
Published: 2020-08-06 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: -12.45%
results
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Published: 2020-09-08 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: -75.89%
H: 9.87%
C: 0.0%
results sclerosis phase 3 treatment topline
Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
Published: 2020-10-06 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: -41.27%
H: 15.32%
C: 9.01%
treatment phase 2b fibrosis cystic fibrosis
Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
Published: 2020-10-08 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: -2.48%
H: 6.78%
C: 4.24%
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
Published: 2020-10-21 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 2.08%
H: 1.0%
C: -5.88%
Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020
Published: 2020-10-23 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: -1.44%
H: 6.34%
C: -1.46%
phase 2b fibrosis cystic fibrosis
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
Published: 2020-11-03 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 0.98%
H: 5.83%
C: 3.88%
results
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
Published: 2020-11-09 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 2.65%
H: 5.17%
C: 5.17%
sclerosis
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
Published: 2020-11-10 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: -2.62%
H: 2.69%
C: 2.69%
results
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Published: 2020-11-12 (Crawled : 22:15) - globenewswire.com
CRBP | $37.74 0.11% 0.13% 450K
|
Health Technology
|
| O: 0.0%
H: 29.51%
C: 13.11%
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
PEGY | $0.0566 23.58% 15.65% 11M
|
Manufacturing
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
LUCY | $0.2545 9.93% 13.94% 66K
|
n/a
PEB 4 | $15.45 2.45% 10.46% 130
|
Finance
MARA | $19.44 10.77% 10.28% 630K
|
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.